Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

BACKGROUND: The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC. METHODS: Overall, 95 patients received pemetrexed 500 mg/m(2 )i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B1...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Francesca, Bearz, Alessandra, Pampaloni, Gianni
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529337/
https://www.ncbi.nlm.nih.gov/pubmed/18667090
http://dx.doi.org/10.1186/1471-2407-8-216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529337/
https://www.ncbi.nlm.nih.gov/pubmed/18667090
http://dx.doi.org/10.1186/1471-2407-8-216

Ejemplares similares